６－（１－甲基－１Ｈ－吡唑－４－基）－２－｛３－〔５－（２－嗎啉－４－基－乙氧基）－嘧啶－２－基〕－苄基｝－２Ｈ－噠嗪－３

发明人:: BECKER, AXEL,贝克　艾西尔,貝克　艾西爾,KUEHN, CLEMENS,可汉　克雷曼,可漢　克雷曼,SAAL, CHRISTOPH,赛尔　克里斯多夫,賽爾　克里斯多夫,SCHADT, OLIVER,史其德　奥利佛,史其德　奧利佛,DORSCH, DIETER,朵齐　狄亚特,朵齊　狄亞特,KRIEGBAUM, EVA,卡礼宝　伊娃,卡禮寶　伊娃,STIEBER, FRANK,史泰伯　法兰,贝克艾西尔,貝克艾西爾,可汉克雷曼,可漢克雷曼,赛尔克里斯多夫,賽爾克里斯多夫,史其德奥利佛,史其德奧利佛,朵齐狄亚特,朵齊狄亞特,卡礼宝伊娃,卡禮寶伊娃,史泰伯法兰

摘要：: The present invention relates to 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate, its sol-vates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.本發明係關於一種6-(1-甲基-1H-吡唑-4-基)-2-{3-[5-(2-嗎啉-4-基-乙氧基)-嘧啶-2-基]-苄基}-2H-噠嗪-3-酮之二氫磷酸鹽、其溶劑合物及其結晶變體。本發明另外係關於一種製備此等結晶變體之方法，以及其在由激酶信號轉導之抑制、調節及/或調整，詳言之由酪胺酸激酶之抑制所引起、介導及/或傳播的生理及/或病理生理病狀、例如諸如癌症之病理生理病狀之治療及/或預防中的用途。